A pediatrician examines a baby held by a parent during a checkup

Photo: Unsplash

Respiratory syncytial virus (RSV) season got off to a late start this year, but activity has stayed elevated longer than usual — enough that most states have extended eligibility for RSV immunizations through the end of April. Here's what's actually changed, and what it means if you have a baby at home.

What's happening this season

Since the season began last fall, there have been more than 46,000 pediatric hospital admissions for RSV in the U.S., the large majority in children under 5. Because the season started later than typical and cases have remained high, most state health departments have extended the window for eligible infants and toddlers to receive RSV immunization through April, rather than cutting it off earlier in the year as in past seasons.

The current AAP recommendations

Advertisement

Nirsevimab vs. clesrovimab: what's the difference?

Both are monoclonal antibody products that give babies short-term protection against severe RSV disease — they aren't vaccines in the traditional sense, since they don't train the immune system to produce its own antibodies, but rather provide the antibodies directly. Nirsevimab is approved for a broader age range, while clesrovimab is authorized specifically for infants under 8 months entering their first season.

What to do if you're not sure your baby is covered

If you're unsure whether your baby already received an RSV immunization, or whether you got Abrysvo during pregnancy, your pediatrician's office can check your child's immunization record and let you know whether anything is recommended before the season winds down. Given the extended window this year, it's worth asking at your next visit rather than assuming the season has already ended.

Signs of severe RSV to watch for

Any of these warrant an urgent call to your pediatrician or a trip to urgent care or the ER, especially in infants under 6 months.